HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tobias Neumann-Haefelin Selected Research

Antidotes

1/2016Estimating the Quantitative Demand of NOAC Antidote Doses on Stroke Units.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tobias Neumann-Haefelin Research Topics

Disease

21Stroke (Strokes)
08/2021 - 08/2004
8Ischemic Stroke
01/2020 - 10/2007
5Infarction (Infarctions)
09/2010 - 01/2004
4Cerebral Hemorrhage
01/2020 - 08/2006
4Atrial Fibrillation
01/2016 - 07/2014
3Intracranial Hemorrhages (Intracranial Hemorrhage)
01/2020 - 10/2007
3Hemorrhage
01/2020 - 10/2015
3Brain Ischemia (Cerebral Ischemia)
11/2009 - 10/2005
2Hematoma
01/2020 - 02/2015
2Pathologic Constriction (Stenosis)
10/2010 - 03/2010
2Ischemia
10/2010 - 11/2007
2Brain Injuries (Brain Injury)
10/2010 - 11/2007
2Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
11/2007 - 07/2005
1Drug-Related Side Effects and Adverse Reactions
10/2015
1Thrombosis (Thrombus)
10/2015
1Transient Ischemic Attack
02/2013
1Embolic Stroke
01/2013
1Lymphopenia (Lymphocytopenia)
11/2009
1Hypoxia (Hypoxemia)
11/2007
1Demyelinating Diseases (Demyelinating Disease)
12/2006
1Vomiting
05/2004

Drug/Important Bio-Agent (IBA)

8AnticoagulantsIBA
01/2017 - 07/2014
4Tissue Plasminogen Activator (Alteplase)FDA Link
01/2020 - 10/2005
4Vitamin KFDA Link
01/2017 - 07/2014
3DabigatranFDA Link
01/2020 - 10/2015
3N(4)-oleylcytosine arabinosideIBA
01/2016 - 01/2015
3Pharmaceutical PreparationsIBA
10/2015 - 12/2009
2edoxabanIBA
10/2015 - 10/2015
2apixabanIBA
10/2015 - 10/2015
2RivaroxabanIBA
10/2015 - 10/2015
2Reactive Oxygen Species (Oxygen Radicals)IBA
10/2010 - 11/2007
2NADPH Oxidases (NAD(P)H oxidase)IBA
10/2010 - 11/2007
2Fibrinolytic Agents (Antithrombotic Agents)IBA
07/2007 - 10/2005
2Biomarkers (Surrogate Marker)IBA
07/2005 - 09/2004
1idarucizumabIBA
01/2020
1AntidotesIBA
01/2016
1ThrombinFDA Link
10/2015
1Factor Xa (Coagulation Factor Xa)IBA
10/2015
1CreatinineIBA
07/2014
1prolinedithiocarbamate (PDTC)IBA
09/2010
1AntioxidantsIBA
09/2010
1NF-kappa B (NF-kB)IBA
09/2010
1pyrrolidine dithiocarbamic acidIBA
09/2010
1p38 Mitogen-Activated Protein KinasesIBA
09/2010
1SphingolipidsIBA
04/2010
1microplasminIBA
12/2009
1Immunosuppressive Agents (Immunosuppressants)IBA
11/2009
1LipidsIBA
11/2009
1SphingosineIBA
11/2009
1Fingolimod Hydrochloride (FTY720)FDA Link
11/2009
1CytokinesIBA
11/2009
1sphingosine 1-phosphate (sphingosine-1-phosphate)IBA
11/2009
1Oxidoreductases (Dehydrogenase)IBA
11/2007
1Clostridium difficile lethal toxin BIBA
11/2007
1Atorvastatin (Lipitor)FDA Link
11/2007
1Coenzyme A (CoA)IBA
11/2007
11- cyclohexyl- 3- (2- (4- morpholinyl)ethyl)carbodiimideIBA
12/2006
1Indicators and Reagents (Reagents)IBA
11/2006
1Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
08/2006
1Proteins (Proteins, Gene)FDA Link
09/2004
1N-acetylaspartate (N-acetyl aspartate)IBA
08/2004
1Lactic Acid (Lactate)FDA LinkGeneric
08/2004
1thiamine triphosphorate (TTP)IBA
01/2004

Therapy/Procedure

13Therapeutics
08/2021 - 08/2006
4Thrombolytic Therapy
05/2009 - 07/2007
3Length of Stay
01/2020 - 12/2012
2Thrombectomy
12/2020 - 04/2016
2Stents
10/2010 - 03/2010
1Anticoagulation Reversal
02/2015
1Secondary Prevention
07/2014
1General Anesthesia
01/2013
1Drug Therapy (Chemotherapy)
12/2012
1Aftercare (After-Treatment)
03/2010
1Contraindications
05/2004